BMS-927711(Rimegepant)
≥99.5%
- Product Code: 110199
Alias:
Related CAS number: 1374024-48-2
CAS:
1289023-67-1
Molecular Weight: | 534.56 g./mol | Molecular Formula: | C₂₈H₂₈F₂N₆O₃ |
---|---|---|---|
EC Number: | MDL Number: | ||
Melting Point: | Boiling Point: | ||
Density: | Storage Condition: | -20°C, dark, dry |
Product Description:
Used primarily for the acute treatment of migraines in adults, it works by blocking the activity of calcitonin gene-related peptide (CGRP) receptors, which play a key role in migraine pathophysiology. It is administered orally as a tablet, offering a non-invasive option for patients seeking relief from migraine symptoms. Its efficacy in reducing migraine pain and associated symptoms like nausea and sensitivity to light and sound has been demonstrated in clinical trials. Additionally, it is considered a favorable option for those who prefer to avoid traditional migraine medications such as triptans, especially in patients with cardiovascular risk factors. The drug is also being explored for its potential in preventing migraines, although its primary use remains in acute treatment.
Product Specification:
Test | Specification |
---|---|
Appearance | White To Off-White Solid |
Purity (%) | 99 |
Infrared Spectrum | Conforms To Structure |
NMR | Conforms To Structure |
Sizes / Availability / Pricing:
Size (g) | Availability | Price | Quantity |
---|---|---|---|
0.005 | 10-20 days | $707.87 |
+
-
|
0.010 | 10-20 days | $1,140.45 |
+
-
|
0.050 | 10-20 days | $3,775.30 |
+
-
|
BMS-927711(Rimegepant)
Used primarily for the acute treatment of migraines in adults, it works by blocking the activity of calcitonin gene-related peptide (CGRP) receptors, which play a key role in migraine pathophysiology. It is administered orally as a tablet, offering a non-invasive option for patients seeking relief from migraine symptoms. Its efficacy in reducing migraine pain and associated symptoms like nausea and sensitivity to light and sound has been demonstrated in clinical trials. Additionally, it is considered a favorable option for those who prefer to avoid traditional migraine medications such as triptans, especially in patients with cardiovascular risk factors. The drug is also being explored for its potential in preventing migraines, although its primary use remains in acute treatment.
Mechanism | - |
Appearance | - |
Longevity | - |
Strength | - |
Storage | - |
Shelf Life | - |
Allergen(s) | - |
Dosage (Range) | - |
Recommended Dosage | - |
Dosage (Per Day) | - |
Recommended Dosage (Per Day) | - |
Mix Method | - |
Heat Resistance | - |
Stable in pH range | - |
Solubility | - |
Product Types | - |
INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :